Trinity Biotech Receives Gold Classification for HbA1c Analyser Despite Financial Challenges.

Trinity Biotech's Premier Hb9210 HbA1c Analyser has received the Gold Classification from the International Federation of Clinical Chemistry and Laboratory Medicine for 2026, the highest level of manufacturer certification. However, the company faces significant financial challenges with declining revenue and profitability metrics. Trinity Biotech's financial health analysis shows a revenue growth rate of -41.5% over the past three years, negative net margins of -51.64%, and a debt-to-equity ratio of -2.27, indicating high leverage. The company's valuation metrics also reflect its challenging financial position with a P/S ratio of 0.15, significantly below the industry median.